New imaging reveals how CS1 drug may reshape lung arteries in PAH patients
NCT ID NCT06907693
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the drug CS1 changes the structure of small lung arteries in people with pulmonary arterial hypertension (PAH). Seven patients already taking CS1 in an expanded access program had special CT scans at the start and after 12 months. The goal was to see if CS1 can help reverse harmful blood vessel changes, which could improve treatment for PAH.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Prisma Health
Greenville, South Carolina, 29605, United States